Eli Lilly's Solanezumab and Johnson & Johnson/Pfizer's Bapineuzumab Have the Potential to Slow the Rate of Neurodegeneration and Cognitive Decline, According to Findings from Decision Resources
BURLINGTON, Mass., Sept. 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the emergence of new agents that have the potential to affect disease progression, the Alzheimer's disease drug market will more than triple, from $4.3 billion in 2009 to $13.3 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The Pharmacor 2010 findings from the topic entitled Alzheimer's Disease reveal that growth will be driven primarily by the first biologic agents to enter the market—Eli Lilly's solanezumab and Johnson & Johnson/Pfizer's bapineuzumab. These anti-beta-amyloid monoclonal antibodies (MAbs), which have the potential to slow the rate of neurodegeneration and cognitive decline, together will earn more than $6.9 billion in the world's major pharmaceutical markets in 2019.
Currently, the market for Alzheimer's disease therapies is dominated by acetylcholinesterase inhibitors (AChEIs), which treat only cognitive symptoms without modifying the course of the disease. Although interviewed experts indicate that the anti-beta-amyloid MAbs have the most clinical and commercial promise in Alzheimer's disease, continued use of symptomatic agents such as the AChEI donepezil (Eisai/Pfizer's Aricept, Bracco's Memac) will help to maintain the AChEI drug class over the next decade.
"Despite increased generic competition and the launch of more-expensive and potentially more-efficacious therapies, AChEI sales will be buoyed through 2019," said Decision Resources Director Bethany Kiernan, Ph.D. "This will be largely due to an overall market expansion driven by increases in the number of drug-treated patients but also, to a lesser extent, by the launch of new formulations of branded AChEIs."
Pharmacor Analyst Call
Media members are welcome to attend our upcoming Pharmacor analyst call entitled Potential Blockbuster Derailed: Eli Lilly Discontinues Development of Semagacestat for Alzheimer's Disease. This online presentation will be held on September 8, 2010 at 10 a.m. U.S. Eastern Time. For more information, please contact Christopher Comfort at [email protected].
About Pharmacor 2010
The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources, Inc.
SOURCE Decision Resources